4225 EXECUTIVE SQUARE, LA JOLLA, CA
Investor Presentation
Zura Bio Limited Approves Amended 2023 Equity Incentive Plan
Director Resignation - Someit Sidhu Steps Down from Zura Bio Board
Reports First Quarter 2026 Financial Results and Recent Corporate Updates
Annual Report to Security Holders
CFO Departure - Eric Hyllengren Separated from Zura Bio Limited
Reports Full Year 2025 Financial Results and Recent Corporate Updates
To Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Submission Upload
Correspondence